DIMERIX LIMITED (DXB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

DXB

DXB - DIMERIX LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.61

23 May
2025

0.025

OPEN

$0.59

4.27%

HIGH

$0.63

4,354,583

LOW

$0.59

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.4 M
Book Value Per Share xxxxxxxxxxxxxxx3.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.2 M
Net Profit Margin xxxxxxxxxxxxxxx-4,190.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-141.42 %
Return on Invested Capital xxxxxxxxxxxxxxx-141.01 %
Return on Assets xxxxxxxxxxxxxxx-68.53 %
Return on Equity xxxxxxxxxxxxxxx-141.42 %
Return on Total Capital xxxxxxxxxxxxxxx-166.81 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx15.43

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx21 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

07/05/2025

1

Buy

$1.58

159.02%

Dimerix has licensed US rights for DMX-200 to Amicus Therapeutics with a deal value of US$590m compared to Petra Capital's estimate of US$370m. The upfront payment of US$30m also exceeded the broker's US$20m estimate.

DMX-200 is used for treating Focal Segmental Glomerulosclerosis, a rare and serious kidney disease.

This outcome significantly de-risks commercialisation, suggests the analyst, and also affirms strong industry interest. Additionally, Dimerix’s balance sheet is strengthened.

Amicus views DMX-200 as a potential blockbuster and its lead late-stage pipeline asset, with future development expected beyond the initial FSGS indication. 

Including this agreement, Dimerix now stands to receive circa $1.4bn plus royalties across four licensing deals, observes Petra Capital.

Petra forecasts an uplift in FY26 profit of 68% and raises its target price to $1.58 from $1.28. Buy retained.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.60 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.70 cents.
Access Extra Coverage Research History >

DXB STOCK CHART

FNArena News on DXB

1
Australian Broker Call *Extra* Edition – May 08, 2025

May 08 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 07, 2025

May 07 2025 - Daily Market Reports
3
Next Week At A Glance – 5-9 May 2025

May 02 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – May 01, 2025

May 01 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Feb 24, 2025

Feb 24 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
2
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
3
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
4
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
5
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
6
CSL Shares Breaking Free

Jul 23 2024 - Technicals
7
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
8
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
9
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
10
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps